Last reviewed · How we verify
NCT04119570
CKD Report Card Pilot Trial
NA trial testing CKD Report Card in CKD in 50 participants. Completed in 15 September 2018.
15 September 2018
Quick facts
| Lead sponsor | University of Chicago |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 50 |
| Start date | 15 May 2018 |
| Primary completion | 15 September 2018 |
| Estimated completion | 15 September 2018 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CKD Report Card
Conditions studied
- CKD — all drugs for CKD →
Sponsor
University of Chicago
Who can join
Adults 18 to 70, any sex, with CKD. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The investigators will study physician-patient communication at the UCMC nephrology fellow clinic and to test an intervention, the CKD Report Card, to improve that communication and patient knowledge of CKD.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
CKD Knowledge and CKD Report Card Use During a Nephrology Encounter: A Randomized Trial.
Bowman J, Zhou C, Zasadzinski L, Zhu M, et al · · 2025 · PMID 40321972 · DOI 10.1016/j.xkme.2025.100991
Verify or expand the search:
- PubMed search for NCT04119570
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CKD
Currently open trials in the same condition.
- NCT07312981 — The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations · recruiting
- NCT06892249 — Suitability of Two Flavours of a High-energy, Low-protein Formula (Renalive® LP) in Chronic Kidney Disease Stage 3b-5 Ou · NA · recruiting
- NCT07062952 — Kidney-protective Intervention With Salt Substitute After Kidney Tumor Surgery · NA · recruiting
- NCT07182942 — The Effect and Mechanism of Xiqing Regulating Intestinal Homeostasis on Drug Efficacy of Chronic Kidney Disease · Phase 4 · recruiting
- NCT06775028 — Integrated Approach in Frail Older People with Atrial Fibrillation · NA · recruiting
Other University of Chicago trials
Trials by the same sponsor.
- NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
- NCT07354100 — Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy · Phase 1, PHASE2 · not yet recruiting
- NCT06446661 — Using Text Messages to Improve Oral Chemotherapy for Adolescents and Adults With Acute Lymphoblastic Leukemia · NA · not yet recruiting
- NCT07179315 — A Study Comparing Two Immunotherapy Options for Human Papillomavirus Positive HPV-Positive Head and Neck Cancer After Tr · Phase 2 · not yet recruiting
- NCT07126561 — Trastuzumab Deruxtecan to Treat HER2 + Newly Diagnosed Metastatic GI Cancers · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04119570 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Chicago
- Last refreshed: 6 May 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04119570.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing